摘要
DPP-4抑制剂与SGLT2抑制剂联合治疗,可以在减轻副作用的基础上更加有效地降低2型糖尿病患者的血糖,但是对于不同剂量的组合,仍需大量临床试验以评估其临床疗效和安全性,使临床医生根据T2DM病人的具体情况选择治疗药物的组合。
DPP-4 inhibitors combined with SGLT2 inhibitors can reduce blood glucose more effectively in patients with type 2 diabetes on the basis of lighter side effects.A large number of clinical trials are still needed to evaluate clinical efficacy and safety for different dose combinations,so that clinicians can select better combinations of therapeutic drugs according to the specific conditions of patients with T2DM.
作者
安建中
洪蕾
乔世刚
王琛
AN Jian-zhong;HONG Lei;QIAO Shi-gang;WANG Chen(Institute of Clinical Medicine Research,Suzhou Hospital(West District)Affiliated to Nanjing Medical University,Suzhou Science and Technology Town Hospital,Suzhou 215153;Department of Anesthesiology and Perioperative Medicine,Suzhou Hospital(West District)Affiliated to Nanjing Medical University,Suzhou Science and Technology Town Hospital,Suzhou 215153)
出处
《药学与临床研究》
2018年第2期111-114,共4页
Pharmaceutical and Clinical Research
基金
苏州市科技计划发展项目(SS201756)
